Targeted therapies: Afatinib—new therapy option for EGFR-mutant lung cancer

作者: A Yu Helena , William Pao

DOI:

关键词:

摘要: On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients.

参考文章(0)